Covax on track as pact signed with Pfizer/BioNTech for 40 million doses
January 23, 2021
Vaccines from AZ-Oxford, SII in the pipeline The Covax facility is on track to deliver two billion doses by the year-end, the World Health Organization director general Tedros Adhanom Ghebreyesus said, announcing an agreement signed with the Pfizer-BioNtech combine for their Covid-19 vaccine.
The WHO-supported Covax initiative had signed an agreement with Pfizer/BioNTech for up to 40 million doses of its vaccine, he said. Theirs is the only one to have got the WHO’s emergency use listing.
Additionally, he said, pending WHO emergency use listing, about 150 million doses of the AstraZeneca/Oxford vaccine would be available for distribution by Covax in the first quarter of this year. India’s Serum Institute of India (SII) has an alliance to produce and market the AZ-Oxford vaccine.
COVAX Announces new agreement, plans for first deliveries
COVAX Announces new agreement, plans for first deliveries 22 January 2021 Reading time:
COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.
Additionally, COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in Q1 2021, via existing agreements with the Serum Institute of India (SII) and AstraZeneca.
COVAX is therefore on track to deliver at least 2 billion doses by the end of the year, including at least 1.3 billion doses to 92 lower income economies in the Gavi COVAX AMC.
Coronavirus: COVAX announces new agreement, plans for first deliveries
COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in Q1 2021
GENEVA, Switzerland, January 22, 2021/APO Group/
COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements; additionally, COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in Q1 2021, via existing agreements with the Serum Institute of India (SII) and AstraZeneca;
Coronavirus: COVAX announces new agreement, plans for first deliveries einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
GENEVA, Jan. 22 (Xinhua) COVAX, the global initiative led by the World Health Organization (WHO) to ensure rapid and equitable access to COVID-19 vaccines for all countries, said on Friday that it will purchase up to 40 million doses of the Pfizer-BioNTech vaccine. Rollout of the Pfizer-BioNTech vaccine, which has already received WHO emergency use listing, will commence with the successful negotiation and execution of supply agreements, according to a COVAX announcement. The global initiative also confirmed that it will exercise an option to receive its first 100 million doses of the AstraZeneca/Oxford University-developed vaccine manufactured by Serum Institute of India (SII), as per an existing agreement with the SII. The majority of the 100 million doses are earmarked for delivery in the first quarter of the year.